Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

Cost of Revenue

$446.00K

TTM · Period ending: · USD

LCTX logo

LCTX Cost of Revenue

Latest reported$446.00K
LCTX TTM Cost of Revenue ($600.00K → $446.00K)
High-resolution chart · PNG

LCTX cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Lineage Cell Therapeutics, Inc. Common Stock Cost of Revenue — Trailing twelve months (TTM) (USD)
Period endingCost of Revenue (USD)
446,000
298,000
146,000
234,000
267,000
272,000
509,000
786,000
917,000
1,000,000
846,000
517,000
583,000
671,000
728,000
830,000
1,580,000
1,490,000
1,426,000
1,336,000
453,000
403,000
385,000
394,000
406,000
438,000
412,000
341,000
262,000
261,000
302,000
304,000
321,000
220,000
168,000
134,000
140,000
230,000
398,000
528,000
902,000
1,067,000
1,106,167
1,179,139
978,040
969,305
837,052
836,502
812,279
741,825
792,660
730,593
693,649
596,756
434,275
273,920
122,702
63,600
43,332
43,332
24,816
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-19,328
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.